Compare ADX & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | ADX | ARQT |
|---|---|---|
| Founded | N/A | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.8B | 3.3B |
| IPO Year | 1996 | 2020 |
| Metric | ADX | ARQT |
|---|---|---|
| Price | $22.51 | $24.48 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $31.86 |
| AVG Volume (30 Days) | 229.5K | ★ 1.2M |
| Earning Date | 01-01-0001 | 05-25-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 88.79 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $376,072,000.00 |
| Revenue This Year | N/A | $34.46 |
| Revenue Next Year | N/A | $29.77 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 91.34 |
| 52 Week Low | $16.50 | $11.86 |
| 52 Week High | $23.85 | $31.77 |
| Indicator | ADX | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 36.84 | 42.68 |
| Support Level | $22.18 | $22.26 |
| Resistance Level | $23.51 | $27.65 |
| Average True Range (ATR) | 0.28 | 1.53 |
| MACD | -0.05 | -0.25 |
| Stochastic Oscillator | 7.43 | 27.73 |
Adams Diversified Equity Fund Inc is a diversified investment company. It is an internally managed closed-end fund whose investment objectives are the preservation of capital, the attainment of reasonable income from investments, and an opportunity for capital appreciation. It invests a majority of its assets in very liquid S&P 500 stocks, and has broad flexibility in the selection of stocks, but maintains a sector neutral approach. The fund has a diversified equity portfolio which consists of securities of companies from energy, consumer staples, information technology, financials, and other sectors.
Arcutis Biotherapeutics Inc is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Its current portfolio is comprised of differentiated topical and systemic treatments with potential to treat immune-mediated dermatological diseases and conditions. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population. The Company has one reportable segment relating to the development and commercialization of treatments for dermatological diseases.